计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Q649776-5mg |
5mg |
期货 ![]() |
| |
| Q649776-10mg |
10mg |
期货 ![]() |
| |
| Q649776-25mg |
25mg |
期货 ![]() |
| |
| Q649776-50mg |
50mg |
期货 ![]() |
| |
| Q649776-100mg |
100mg |
期货 ![]() |
|
| 规格或纯度 | ≥99% |
|---|---|
| 英文名称 | QC6352 |
| 生化机理 | QC6352 是一种可口服的选择性强效 KDM4C 抑制剂,其 IC 50 为 35 nM。 |
| 储存温度 | 避光,-80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
QC6352 is an orally available, selective and potent KDM4C inhibitor with an IC 50 of 35 nM In Vitro QC6352 is a potent KDM4C inhibitor with an IC 50 of 35±8 nM. In a concentration-dependent manner QC6352 dramatically reduces the anchorage-independent sphere-forming capacity of BCSC1 and BCSC2. QC6352 blocks proliferation and self-renewal of BCSCs. As shown by western blot analysis the protein levels of (Epidermal growth factor receptor) EGFR are reduced in both BCSC1 and BCSC2 upon treatment with QC6352. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo QC6352 strongly affects tumor growth and final tumor weight of both BCSC1 and BCSC2 xenografts. Treatment with QC6352 is well tolerated and does not affect body weight of the mice. Results demonstrate that treatment with the KDM4 inhibitor QC6352 blocks BCSC xenograft tumor growth. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Assay Cells are detached by Accutase and counted. 1×10 3 single BCSC1 and BCSC2 cells are seeded as triplicates in 50% Matrigel into individual wells of 24-well ultra-low attachment plates in serum-free MSC medium. After 7 days, spheres over 50 μm diameter are counted for QC6352- and QC6688-treated and control cells and spheres over 20 μm diameter are counted for paclitaxel-treated and control cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal administration Mice: When tumors reach a palpable size of 3 mm 3 , mice are treated with vehicle (control) or QC6352. The inhibitor is administered daily to mice via oral gavage at 10 mg/kg. Control animals receive vehicle only. Animals are monitored twice weekly for weight and tumor growth . aladdin has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:KDM4 |
| 纯度 | ≥99% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 3-[[(1R)-6-(N-methylanilino)-1,2,3,4-tetrahydronaphthalen-1-yl]methylamino]pyridine-4-carboxylic acid |
| INCHI | 1S/C24H25N3O2/c1-27(19-8-3-2-4-9-19)20-10-11-21-17(14-20)6-5-7-18(21)15-26-23-16-25-13-12-22(23)24(28)29/h2-4,8-14,16,18,26H,5-7,15H2,1H3,(H,28,29)/t18-/m0/s1 |
| InChi Key | XSMABFRQESMONQ-SFHVURJKSA-N |
| Smiles | CN(C1=CC=CC=C1)C2=CC3=C(C=C2)C(CCC3)CNC4=C(C=CN=C4)C(=O)O |
| Isomeric SMILES | CN(C1=CC=CC=C1)C2=CC3=C(C=C2)[C@@H](CCC3)CNC4=C(C=CN=C4)C(=O)O |
| PubChem CID | 118598059 |
| MeSH Entry Terms | QC6352 |
| 分子量 | 387.47 |
| 溶解性 | DMSO : 16.67 mg/mL (43.02 mM; Need ultrasonic) |
|---|---|
| 分子量 | 387.500 g/mol |
| XLogP3 | 5.300 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 5 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 387.195 Da |
| 单同位素质量Monoisotopic Mass | 387.195 Da |
| 拓扑极表面积Topological Polar Surface Area | 65.500 Ų |
| 重原子数Heavy Atom Count | 29 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 536.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |